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Background: The selection pressure imposed by the parasite has a functional consequence on the immune genes,
leading to altered immune function in which regulatory T cells (Tregs) induced by parasites during infectious
challenges modulate or thwart T effector cell mechanism.
Methods: We identified and investigated regulatory polymorphisms in the immune gene IL2 and its receptor IL2R
alpha (also known as CD25) in Gabonese individuals exposed to plentiful parasitic infections.
Results: We identified two reported variants each for IL2 and its receptor IL2R alpha gene loci. Also identified were
two novel variants, -83 /-84 CT deletions (ss410961576) for IL2 and -409C/T (ss410961577) for IL2R alpha. We further
validated all identified promoter variants for their allelic gene expression using transient transfection assays. Three
promoter variants of the IL2 locus revealed no significant expression of the reporter gene. The identified novel
variant (ss410961577C/T) of the IL2R alpha revealed a significant higher expression of the reporter gene in
comparison to the major allele (P<0.05). In addition, the rs12722616C/T variant of the IL2R alpha locus altered the
transcription factor binding site TBP (TATA box binding protein) and C/EBP beta (CCAAT/enhancer binding protein
beta) that are believed to regulate the Treg function.
Conclusions: The identification and validation of such regulatory polymorphisms in the immune genes may
provide a basis for future studies on parasite susceptibility in a population where T cell functions are compromised.
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Parasites increase their survival rate in the host by
means of a complex interaction with the host immune
system. However understanding such interaction on the
part of the host and parasite during infections still
remains a fundamental issue. In such processes, it is
believed that the host regulatory T (Tregs) cells play an
essential role [1,2]. The parasite induces a regulatory T
cell (Tregs) population that can modulate the magnitude
of effector T cell functions thereby leading to a sub-
tle immune response during infections [3]. The regula-
tory T cell populations remain diverse; a few of them
are induced during infections while the others are* Correspondence: velavan@medizin.uni-tuebingen.de
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reproduction in any medium, provided the orconsidered to be natural Tregs vitally implicated in
averting autoimmunity [4]. Tregs are believed to influ-
ence host inflammatory and immune responses via
mechanisms of cell-to-cell contact, inhibitory cytokines
and cytokine deprivation [3]. Pathogen driven selection
operating on the host immune genes can impose a nu-
cleotide variation in the primed sequence whereby sub-
stantial changes in gene expression is directed [2].
Human gene expression is a controlled transcriptional
process in the promoter region of a given gene and is
regulated by cis-acting DNA sequence elements. Any
nucleotide alteration in the promoter region is likely to
alter the gene expression, reflecting the level of suscepti-
bility to a parasitic infection as well as Treg expression
[5]. A number of loci are known to be associated with
Treg activity. Genes such as IL10, IL13, STAT6,
TNFRSF18, TLRs and FOXP3 have been as key players inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interleukin 2 (IL2) and its receptor IL2R alpha (CD25)
that are known to modulate the proliferation and differ-
entiation of T cells and are essential for peripheral
homeostasis of the CD4+CD25+ Tregs [8].
The human IL2 is located on the q arm of the
chromosome 4 (specifically 4q27) and its receptor IL2R
alpha (CD25) maps to the p arm of the chromosome 10
(specifically 10p15.1). The human IL-2 is primarily pro-
duced by T cells in response to antigenic stimulation
and is a major mediator of the immune response [9].
Studies have demonstrated that IL-2 is essential for the
proliferation and maintenance of Tregs and can disrupt
Treg homeostasis [10,11], whereas the IL-2R plays a sig-
nificant role in Treg differentiation and proliferation
[12]. Tregs have been shown to constitutively express
IL-2R (CD25), allowing Tregs to respond to low levels of
IL-2 produced by conventional CD4+ T cells [10,11].
The removal of IL-2 from activated T cells can lead to a
deprivation of cells, which is indicated by studies on
IL2-deficient mice [13]. The IL-2 receptor has three
chains, α, β and γ, which constitute the high affinity IL2
receptor. The IL2R alpha (CD25) is responsible for acti-
vating the IL2 signaling complex and regulates the signal
transduction [14,15]. The IL2-R alpha subunit forms the
largest of the three IL-2/IL2-R interfaces. Association of
α chain with the β and γ heterodimer creates a receptor
with a much higher affinity for IL-2 than the β and γ
chains receptor [16]. Antigen recognition by the T cell
receptor induces the synthesis or activation of the tran-
scription factors such as NFAT, AP-1, and NFκB, which
are located in the promoter region of the IL2 gene and
are essential for activating its transcription [17]. Studies
have pointed to the single nucleotide polymorphisms
(SNPs) located within the upstream −10 kb of the IL2
gene that includes the promoter region, and possibly
even beyond, thereby contributing to IL2 transcriptional
properties in vivo [18]. The inhibition of IL2R alpha
(CD25) during thymocyte differentiation is related to
IL2R alpha promoter after response to pre-TCR signals
and is essential for the specific response of mature T
cells later on [19]. Additionally studies have shown that
SNPs within IL2R alpha are associated with both Grave’s
disease and Type1 diabetes [20,21]. Reports have indi-
cated that polymorphisms in the genes encoding IL2
are associated with ulcerative colitis, inflammatory
bowel disorder, rheumatoid arthritis and Behcet’s disease
[22-25], whereas the receptor of IL2, the IL2R alpha
variants were associated with type I diabetes and mul-
tiple sclerosis [21,26,27].
In the current study, our goal is to identify regulatory
single nucleotide polymorphisms (SNPs) in the promoter
region of the IL2 and its receptor IL2R alpha (CD25)
gene loci in a Sub-Saharan African population exposedto a wide array of parasitic diseases. In this study, with a
view to identifying regulatory SNPs in the promoter
regions of the IL2 and its receptor IL2R alpha (CD25),
we sequenced the promoter region of such genes as were
upstream of the transcriptional start site, using samples
from 40 unrelated Gabonese individuals. The identified
regulatory SNPs were further validated for their allelic




Forty DNA samples were collected from unrelated
Gabonese individuals and informed written consent for
participation in the study was obtained from all partici-
pants. Blood samples were collected from adult male
patients with uncomplicated malaria at the Medical
Research Unit of the Albert Schweitzer Hospital,
Lambaréné, Gabon, between August and November
2004 [28]. All uncomplicated malaria individuals were
male adults living in malaria-endemic countries; usually
such individuals will not show symptoms of malaria
although carrying parasites in their blood. The study
subjects represent another cohort where we investigated
novel chemotherapy against malaria [29]. To avoid com-
plications arising from unnoticed pregnancy, only males
were chosen. The study was approved by the local ethics
committee of the International Foundation of the Albert
Schweitzer Hospital. Genomic DNA from whole blood
was isolated using QIAamp DNA Blood Mini kit
(Qiagen, Hilden, Germany).
Sequencing and SNP identification
For purposes of sequencing analysis, gene and genomic
sequences of the IL2 (NM_000586) and IL2R alpha
(CD25) (NM_000417) were obtained from the SNPper
database [http://snpper.chip.org/]. PCR primers were
designed to amplify the promoter region of the gene
using the PRIMER3 Software [http:// www genome.wi.
mit.edu/cgi-bin/primer/primer3_www.cgi]. The promoter
regions of the human IL2 and IL2R alpha (CD25) genes
were amplified by polymerase chain reaction (PCR). The
primer pairs employed for amplifying promoter regions
of the IL2 were IL2F: 50-TAAATAAGGCCATAGAA
TGG-30 and IL2R: 50- GTTACATTAGCCCACACT
TA -30. The primer pairs employed to amplify promoter
regions of IL2R alpha were IL2RF: 50- GATCCA
CCCACCTTGGTCTA -30 and IL2RR: 50-GGCAGCC
AGGCACCATGATGAAC -30 (MWG Operon, Germany).
In brief: PCR were carried out in a 20 μl reaction
volumes with 5ng of genomic DNA, 1x PCR buffer (20
mM Tris–HCl pH 8.4, 50 mM KCl, 1.5 mM of MgCl2;
Qiagen), 0.125mM of dNTPs, 0.5mM of each primer
and 1 U Taq DNA polymerase (Qiagen, Hilden,
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USA). Thermal cycling parameters for the amplification
of both IL2 and IL2R alpha were as follows: initial de-
naturation at 94°C for 5min, followed by 40 cycles of
15 sec at 94°C denaturation, 60 sec at 60°C annealing
temperature, 60 sec at 72°C extension, followed by a
final extension of 10 min at 72°C. PCR products were
cleaned up using Exo-SAP-IT (USB, Affymetrix, USA)
and 1μl of the purified product was directly used as
templates for sequencing, using the BigDye terminator
v. 2.0 cycle sequencing kit (Applied Biosystems, USA)
on an ABI 3130 XL DNA sequencer, according to the
manufacturer’s instructions. Polymorphisms in the pro-
moter regions were identified by assembling the
sequences, the respective reference sequences being
obtained from SNPper database (http://snpper.chip.org)
using Codon code Aligner 4.0 software (http://www.
codoncode.com/) and were then reconfirmed visually
from their respective electropherograms.
Cloning and construct preparation
The SNPs identified in the promoter regions had their
polymorphism status reconfirmed for their polymorph-
ism status by subsequent cloning procedures. Those
genomic DNA sequences identified as having SNPs in
the promoter regions of the IL2 and IL2R alpha were
amplified with infusion primers (flanks a 15bp homology
to the linearised pGL3 vector) and were then cloned to a
linearised pGL3 basic vector. In brief, PCR amplifica-
tions were carried out in 50 μl reaction volumes under
the same program conditions as mentioned above. The
amplified PCR products was analyzed by electrophoresis
in 1.5% agarose gels, using a 100 bp DNA ladder mo-
lecular size marker (Invitrogen, Karlsruhe, Germany)
and PCR -products were gel eluted and purified using a
Nucleospin kit (Macherey-Nagel, Düren, Germany) be-
fore being cloned to the pGL3 basic vector using Infu-
sion advantage PCR cloning kit (Clonetech, Mounatain
view, CA). Plasmids were isolated using QIAprepW Spin
Miniprep Kit (Qiagen, Hilden, Germany). To ensure ac-
curacy of the sequenced promoter regions, several inde-
pendent plasmids containing inserts were sequenced in
both directions using appropriate primer pairs. The plas-
mid exhibiting the confirmed polymorphism was
transformed into one shot E. coli (Invitrogen, Karlsruhe,
Germany). Two independent colonies were selected
from these transformations and maxi prep was
performed using Endofree plasmid maxi kit (Qiagen,
Hilden, Germany).
Transient transfection assays
We tested the activities of the observed polymorphic
promoters for both IL2 and IL2R alpha using Jurkat T
cell lines. Basically, four independent transfectionexperiments for each construct in duplicates were per-
formed with Jurkat T cells (DSMZ, Braunschweig,
Germany). Jurkat T cells (0.8X10 6 cells/μl) were grown
in a RPMI 1640 (Sigma-Aldrich, Hamburg, Germany)
supplemented medium containing 10% FBS, 2mM L-
Glutamine and 1% Streptamycin-pencillin substrate
(Invitrogen, Karlsruhe, Germany). Jurkat cells (0.8X10 6
cells/μl) were transfected with TransIT reagent (Mirus
Bio, Madison, USA) as recommended by the manufac-
turer. In brief: 120μl of TransIT reagent was added to
3ml of RPMI 1640 serum free medium (Sigma-Aldrich,
Hamburg Germany), this being then incubated for
20 min at room temperature. Each of the 24 well plates
was then seeded with 0.5ml (0.8X10 6 cells/μl) of Jurkat
T cells along with 500ng of plasmid DNA constructs and
20ng of Renilla, before being allowed to incubate for
20 minutes. After incubation, 52μl of TransIT+RPMI
serum free medium mix were suspended across each
well. The whole procedure was performed in 2X24 well
plate formats. After 24 hours, one plate was induced
with 20ng/ml Phorbol 12-myristate 13-acetate (PMA,
Sigma-Aldrich, Hamburg, Germany) as well as 25μg/ml
Concanavalin A (Sigma-Aldrich, Hamburg, Germany).
After 24 hours cells were harvested by centrifugation,
washed twice with phosphate-buffered saline and lysed
in 100μl of 1x passive lysis buffer (Promega, Mannheim,
Germany). After incubation for 20 min at room
temperature on a rocking platform, 10μl of the lysate
was used to measure luciferase activity in the SIRIUS
luminometer (Berthold detection system, Pforzheim,
Germany). We employed the dual luciferase reporter
assay system (Promega, Mannheim, Germany). For each
experiment, a plasmid expressing constitutively Renilla
luciferase in low amounts was used as a positive control
[30]; while a promoterless plasmid (pGL3 basic) was
integrated as a negative control. Each construct was
measured 8 times, then both stimulated and non stimu-
lated with two different DNA preparations. Relative luci-
ferase activity was calculated as luciferase firefly/
luciferase Renilla multiplied by 1000.
Transcription factor binding search
An extensive search for transcription factor binding
sites for the observed SNPs in the promoter region was




Data were normalized and have been analyzed by
StatView (http://www.statview.com). The mean ratio
(Luciferase/Renilla) across all measurements was consid-
ered for purposes of calculating relative luciferase activ-
ity. The luciferase activity of the two different IL2 and
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analyzed by a t-test (before and after stimulation). In
addition, each constructs activity was compared to the
activity of the major allele (common alleles) in both an
induced and a non induced state. The statistically signifi-
cant level was set as 0.05.
Results
All forty subjects were sequenced for the entire pro-
moter region of the IL2 and IL2R alpha (CD25) and were
investigated for described and novel SNPs. For the IL2
promoter region, two predescribed SNPs (rs2069762T/G
and rs2067006T/A) were observed. In addition we
observed a novel CT deletion at the position −83/-84 in
one individual. This novel SNP was submitted to the
SNPper database and a corresponding ID was obtained
(#ss410961576). The corresponding references SNP ID
(#rs); observed allele frequencies from investigated IL2
gene are summarized in Table 1. In order to characterize
these variants in terms of function, a transient transfec-
tion assay were performed using Jurkat T cells. The ac-
tivity of the three different IL2 promoter variants
analyzed by luciferase activities is compared in Figure 1.
The p-values of the two observed SNP constructs of the
IL2 variant remained insignificant in comparison to the
major allele before and after stimulation (P > 0.05).
When explicitly examined for a transcription factor
binding site in the observed variants of IL2, the
rs2067006T/A variant was found to be positioned on the
transcription site ETS-1, which is a member of the ETS
(E-twenty six) family of transcription factors that func-
tion as transcriptional activators or repressors in numer-
ous genes believed to be involved in stem cell
development, cell senescence, and death. The other two
variants (#ss410961576CTdel and rs2069762T/G) do not
alter any putative transcription factor binding site.
For the IL2R alpha (CD25), two described variants in
the promoter region (rs12722617C/T and rs12722616C/
T) were observed. In addition we observed a novel C/T
variant at the position −409 in two individuals. This
novel SNP was submitted to the SNPper database and aTable 1 Genetic variants identified in the promoter regions o





ss410961576 −83,84 CT deleted ATTTT [CT/-] GAGTT CT/CT
del/del
rs2069762 −100 T>G TTTTA[T/G] GACAA TT
TG
rs2067006 −191 T>A TGTTT[T/A] ATCAA AT
AA
aFrequency corresponds for both allele and genotypes; b: YRI: Yoruba population re
Chinese; NA: data not available.corresponding ID was obtained (#ss410961577). The
corresponding references SNP ID (#rs); observed allele
frequencies from investigated IL2R alpha (CD25) are
summarized in Table 2. The activity of the three differ-
ent IL2 promoter variants analyzed by luciferase activ-
ities is compared in Figure 2. The variant rs12722617C/
T and rs12722616C/T were observed to be in absolute
linkage in all individuals analyzed. The p-values of the
SNP construct (rs12722617C/T + rs12722616C/T) of the
IL2R alpha variant remained insignificant in comparison
to the major allele before and after induction (P >0.05),
but remained significant when compared to the new
variant in a stimulated state (P<0.0005). The observed
novel variant #ss410961577C/T showed significantly
increased activity in comparison to the major allele
(P<0.05). When looked in explicit for transcription fac-
tor binding site in the observed variants of IL2R alpha
(CD25) variants, two variants (rs12722617C/T and
#ss410961577C/T) were found not to alter any putative
transcription factor binding site. However the SNP vari-
ant (rs12722616C/T) which was in linkage disequilib-
rium (LD) with rs12722617C/T is positioned at the
transcription factor binding site TBP (TATA box binding
protein) and C/EBP beta (CCAAT/enhancer binding
protein beta).
Discussion
The underlying idea of the current study is to under-
stand how regulatory SNPs in populations that are nat-
urally exposed to array of parasites contribute to
immune outcome. A significant impact on the diversity
among immune gene families is believed to be attribut-
able to invasion maneuvers performed by the parasites.
Therefore variations in the promoter regions of
these immune system genes can potentially amend
the gene expression levels either by changing specificity
of transcription binding sites or by altering the kinetics
of transcription initiation [7]. In our current
study, we identified two known SNPs (rs2069762T/G
and rs2067006T/A) and one novel CT deletion
(#ss410961576) at the position −83/-84 when screenedf the IL2 gene locus
Analysed
individuals
Allele Frequencya Frequencies (Hapmap YRI,
CEU, CHB)b
39 CT 0.975 NA
1 del 0.025
38 T 0.950 0.034, 0.232, 0.267
2 G 0.050
0 T 0.000 0.000, 0.000, 0.000
40 A 1.000 1.000, 1.000, 1.000
presenting Sub- Saharan African individual group, CEU: European, CHB: Han






















Figure 1 Comparison of the activity of the three identified IL2 promoter variants analyzed by luciferase activities. The ratio of the
relative light units (firefly/renilla) is given. P values are calculated by t-Test from four different experiments performed in duplicates with two
different DNA preparations. Each construct was induced by PMA and ConA. The letters indicate the presence of mutations T/G, CT del and T/A.
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constructs revealed differential luciferase activity com-
pared to the major allele. In the current investigation the
IL2 variant (rs2067006T/A) was considered to be the
major allele, as all the individuals were found to harbor
this particular variant. When compared to the NCBI
HapMap database, the frequencies of the observed SNP
variants (rs2067006T/A and rs2069762T/G of IL2) were
in accordance with Yoruba population of Nigeria which
represents a Sub Saharan African group. The
rs2067006T/A variant is positioned on to the transcrip-
tion site ETS-1, a member of the ETS (E-twenty six) fam-
ily of transcription factors. The ETS-1 DNA-binding
domain recognizes the core consensus DNA in target
genes and acts either as transcriptional activators or
repressors [31]. Recent studies have demonstrated that
ETS-1 belongs to a large protein complex which bindsTable 2 Genetic variants identified in the promoter regions o





rs12722617 −398 C>T TTCGC[C/T] GCATC CC
CT
ss410961577 −409 C>T GGATC[C/T] TTCAG CC
CT
rs12722616 −516 C>T AACAC [C/T] TTATA CC
CT
aFrequency corresponds for both allele and genotypes; b: YRI: Yoruba population re
Chinese; NA: data not available.to the Treg-specific demethylated region (TSDR) in the
FOXP3 locus, thereby restricting the stable FOXP3 ex-
pression in the Tregs [32]. FOXP3 is described as a mas-
ter regulator of natural Tregs development and function
[4], while mature regulatory T cells expressing a non-
functional fusion protein of FOXP3 lack any suppressor
function [33]. Since all the investigated individuals inher-
ited this variant, we believe that the studied population
may have a restricted FOXP3 expression leading to a
subtle T effector cell function.
In our study we also identified two known SNPs
(rs12722617C/T and rs12722616C/T) along with one
novel C/T variant (#ss410961577) at the position −516
when screened for the IL2R alpha (CD25) promoter
region of the IL2R alpha. Both the predescribed
SNP variants of the IL2R alpha (rs12722617C/T and
rs12722616C/T) were observed in linkage in all studiedf the IL2R alpha (CD25) gene locus
Analysed
individuals
Allele Frequencya Frequencies (Hapmap YRI,
CEU, CHB)b
35 C 0.875 0.932, 1.000, NA
5 T 0.125 0.068, 0.000, NA
38 C 0.950 NA
2 T 0.050
35 C 0.875 0.924, 1.000, 1.000
5 T 0.125 0.076, 0.000, 0.000
presenting Sub- Saharan African individual group, CEU: European, CHB: Han















*    P <0.05





Figure 2 The activity of the three identified IL2R alpha promoter variants as compared by luciferase activities. The ratio of the relative
light units (firefly/renilla) is given. P values are calculated by t-Test in four different experiments performed in duplicates with two different DNA
preparations. Each construct was induced by PMA and ConA. The letters indicate the presence of polymorphic variants.
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activity compared to the major allele for the construct
(rs12722617C/T + rs12722616C/T). However the identi-
fied novel variant (#ss410961577C/T) revealed significant
increased activity in comparison to the constructs with
the major allele. This particular novel variant did not
alter any putative transcription factor binding site. How-
ever the variant rs12722616C/T which was in LD with
rs12722617C/T altered the transcription factor binding
site TBP (TATA box binding protein) and C/EBP beta
(CCAAT/enhancer binding protein beta). The TATA box
is a type of promoter sequence that indicates the tran-
scriptional start site whereby a genetic sequence can be
read and decoded. It is named after the conserved DNA
sequence TATAAA. TBP (TATA binding protein) to-
gether with TATA associated factors (TAFS) make the
transcription factor TFIID which binds the TATA box in
combination with other transcription factors (TFIIB,
TFIIA, TFIIE, TFIIF, TFIIH) [34]. All the above transcrip-
tion factors along with RNA polymerase II enzyme form
a transcription initiation complex. Therefore it is pos-
sible that the TATA box in the construct rs12722616C/T
ma contributes to the transcription initiation in vitro in
the Jurkat cells. The other transcription factor C/EBP
beta (CCAAT/enhancer binding protein beta) is believed
to modulate inflammatory processes. A recent study has
demonstrated in an experimental autoimmune enceph-
alomyelitis model that C/EBP expression by dendritic
cells (DC) influences Th17 versus Treg differentiation
but has little or no impact upon Th1 development [35].Examining the HapMap database, all the frequencies of
reported variants of the IL2R alpha loci were found to
be in accordance with the frequencies in the Yoruba
population.
Human IL2 and its receptor IL2R alpha are described
as constituting a potent T cell growth factor and are
mainly produced by activated CD4+ T cells, though also
by naïve CD8+ T cells, dendritic cells, and thymic cells
[36]. Human IL-2 is considered to be vital for the devel-
opment of CD4+CD25+ regulatory T cells [37]. Also
studies have demonstrated that IL-2 also potentially
plays a role in the thymic development of Tregs [38,39].
Studies have shown that polymorphisms in the IL2 are
associated with many diseases including auto immune
diseases. Recent studies have demonstrated that the
studied IL2 promoter variant (rs2069762T/G) is asso-
ciated with Helicobacter pylori infection [40], multiple
sclerosis [41], pathogenesis of childhood lymphoma [42],
pathogenesis of new-onset diabetes after transplantation
(NODAT) [43], measles-specific cellular immunity [44],
a higher risk of acute rejection episodes during kidney
transplantation [45] and in allergic disorders [46]. How-
ever, the role of the described and novel variants of IL2
and IL2R alpha in this study needs to be validated in
terms of the specific role these play in different parasitic
diseases.
Conclusions
In summary, the regulatory SNPs identified in this
current study will provide useful information for
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in populations exposed to many parasitic diseases and
may serve as a basis for backup studies examining dis-
ease susceptibility.
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